A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of GCC19CART for Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.
100 项与 Innovative Cellular Therapeutics, Inc. 相关的临床结果
0 项与 Innovative Cellular Therapeutics, Inc. 相关的专利(医药)
100 项与 Innovative Cellular Therapeutics, Inc. 相关的药物交易
100 项与 Innovative Cellular Therapeutics, Inc. 相关的转化医学